With this appointment, the total number of directors is seven.
Earlier this month, Crew joined Lannett as CEO.
He has more than 25 years of experience in the generic and branded pharmaceutical industries, having served in leadership positions with Cipla North America, a global pharmaceutical company based in Mumbai, India, Teva Pharmaceuticals, Dr. Reddy's Laboratories and Bristol-Myers Squibb.
Prior to his pharmaceutical roles, Crew served in the US Army, where he rose to the rank of Captain.
Crew earned a Bachelor of Arts degree in economics from Pomona College and a Masters of Business Administration degree from Columbia Business School.
Lannett company, founded in 1942, develops, manufactures, packages, markets and distributes generic pharmaceutical products for a wide range of medical indications.
ScinoPharm Taiwan secures first US FDA approval for complex multiple sclerosis generic
ScinoPharm Taiwan's Glatiramer Acetate Injection approved by US FDA
International Isotopes Inc to change name to Radnostix Inc
Galmed Pharmaceuticals reports topline results for combination of Aramchol, Stivarga and metformin
Ingenus Pharmaceuticals' generic equivalent to Premarin receives US FDA approval
EirGenix signs second global exclusive licensing deal with Sandoz
Padagis invests USD36m to expand manufacturing in Minneapolis
Newbury Pharmaceuticals gains Danish approval for generic ivermectin cream